Impilo

Company Overview

Snapshot

Founded in May 2021 by Noam Alon and Tzachi Davidi, Impilo operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its AI-driven diagnostic system. In March 2025, Impilo was highlighted for its potential to simplify rare disease diagnosis.

Business overview

Impilo is a Health Tech & Life Sciences company developing advanced data processing technology to address the challenges of delayed diagnosis, misdiagnosis, and underdiagnosis of patients with complex conditions. Its novel platform leverages natural language processing, machine learning, and data analysis to identify conditions often missed or misdiagnosed, aiming to alleviate patient distress and reduce the burden on healthcare systems. The company operates within the Digital Healthcare and Digital Medical Diagnostics sectors, serving healthcare providers.

Strategic signal

In March 2025, Impilo gained recognition for its innovative approach to diagnosing rare diseases, signaling a potential advancement in medical diagnostics. This highlights the company's progress in developing its AI-driven system and its relevance in addressing critical challenges within the healthcare industry, particularly in improving diagnostic accuracy and efficiency for complex conditions.

Company Intelligence Q&A

What is Impilo's core mission?

Impilo's core mission is to solve the challenge of delayed diagnosis, misdiagnosis, and underdiagnosis of patients with irregular and complex diagnosis pathways, utilizing forefront data processing technology.

When was Impilo founded and by whom?

Impilo was founded in May 2021 by co-founders Noam Alon and Tzachi Davidi.

What technology does Impilo use in its platform?

Impilo's novel platform utilizes natural language processing, machine learning, and data analysis to identify conditions that are often misdiagnosed or undiagnosed.

What problem does Impilo aim to solve in healthcare?

Impilo aims to address the distress caused to patients and the burden on health systems due to misdiagnosed or undiagnosed conditions, particularly rare and complex diseases.

What was a recent notable mention for Impilo?

In March 2025, Impilo was featured for its potential to significantly simplify the diagnosis of rare diseases, indicating progress in its technological development.